Clarissa de Castro Ferreira

Clarissa de Castro Ferreira

Auto-generated profile, based on publicly available information

Clarissa de Castro Ferreira

Escola Superior de Ciências da Saúde da Fundação de Ensino e Pesquisa em Ciências da Saúde do Distrito Federal

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2015 in Anais Brasileiros de Dermatologia
Verified
Journal Article
Open access
PDF file
PKPatricia Shu Kurizky
Patricia Shu Kurizky
CFClarissa de Castro Ferreira
Clarissa de Castro Ferreira
LNLucas Souza Carmo Nogueira
Lucas Souza Carmo Nogueira
LMLicia Maria Henrique da Mota
Licia Maria Henrique da Mota
Psoriasis is a chronic inflammatory disease that affects primarily the skin and joints, with a worldwide incidence of 2-3%. Fifty percent of patients are women, most still diagnosed during childbearing years. Currently,the estimate is that up to 107 thousand deliveries are performed annually in women with psoriasis, a percentage of them in women with moderate to severe disease. Fetal risks in pregnant women with psoriasis derive both from maternal disease and the medications used to control the illness. The purpose of this review is to study the effect of the main drugs used in the treatment of psoriasis and psoriatic arthritis during pregnancy and lactation, with particular focus on disease-modifying anti-rheumatic biological drugs, biological therapies, immunobiologics or biologics.

27 November 2017 in Expert Review of Vaccines
Verified
Journal Article
Closed access
CFClarissa de Castro Ferreira
Clarissa de Castro Ferreira
ACAna Carolina Campi-Azevedo
Ana Carolina Campi-Azevedo
VPVanessa Peruhype-Magalhāes
Vanessa Peruhype-Magalhāes
CCChristiane Costa-Pereira
Christiane Costa-Pereira
CACleandro Pires de Albuquerque
Cleandro Pires de Albuquerque
LMLicia Maria Henrique da Mota
Licia Maria Henrique da Mota
Introduction: The yellow fever vaccine is a live attenuated virus vaccine that is considered one of the most efficient vaccines produced to date. The original 17D strain generated the substrains 17D-204 and 17DD, which are used for the current production of vaccines against yellow fever. The 17D-204 and 17DD substrains present subtle differences in their nucleotide compositions, which can potentially lead to variations in immunogenicity and reactogenicity. We will address the main changes in the immune responses induced by the 17D-204 and 17DD yellow fever vaccines and report similarities and differences between these vaccines in cellular and humoral immunity . This is a relevant issue in view of the re-emergence of yellow fever in Uganda in 2016 and in Brazil in the beginning of 2017. Areas covered: This article will be divided into 8 sections that will analyze the innate immune response, adaptive immune response, humoral response, production of cytokines, immunity in children, immunity in the elderly, gene expression and adverse reactions. Expert commentary: The 17D-204 and 17DD yellow fever vaccines present similar immunogenicity, with strong activation of the cellular and humoral immune responses. Additionally, both vaccines have similar adverse effects, which are mostly mild and thus are considered safe.

1 September 2015 in Revista Brasileira de Reumatologia
Verified
Journal Article
Open access
PAPedro Henrique Tavares Queiroz de Almeida
Pedro Henrique Tavares Queiroz de Almeida
CFClarissa de Castro Ferreira
Clarissa de Castro Ferreira
PKPatricia Shu Kurizky
Patricia Shu Kurizky
LMLuciana Feitosa Muniz
Luciana Feitosa Muniz
LMLicia Maria Henrique da Mota
Licia Maria Henrique da Mota
Sexuality, an integral part of human life and quality of life, is one of those responsible for our individual welfare. Sexual dysfunction can be defined as a change in any component of sexual activity, which may cause frustration, pain and decreased sexual intercourse. Although it is known that chronic diseases, such as rheumatoid arthritis (RA), influence the quality of sexual life, sexual dysfunction is still underdiagnosed, due to two reasons: both patients fail to report the complaint because of shame or frustration, and this subject is rarely called into question by doctors. Rheumatologists are increasingly willing to discuss areas which are not directly related to drug treatment of joint diseases, such as quality of life, fatigue, and education of patients; however, sexuality is rarely addressed. The aim of this review is to present some useful concepts to Rheumatologists for orientation of their patients with RA with respect to sexual function/dysfunction, some considerations concerning the role of these professionals in order to instruct the patient, general notions about sexual function, including practical concepts about the more appropriate sexual positions for patients with RA, and a multidisciplinary approach to sexual dysfunction.

22 January 2013 in Revista Brasileira de Reumatologia
Verified
Journal Article
Open access
PDF file
CFClarissa de Castro Ferreira
Clarissa de Castro Ferreira
LMLicia Maria Henrique da Mota
Licia Maria Henrique da Mota
AOAna Cristina Vanderley Oliveira
Ana Cristina Vanderley Oliveira
JCJozélio Freire de Carvalho
Jozélio Freire de Carvalho
RLRodrigo Aires Corrêa Lima
Rodrigo Aires Corrêa Lima
LNLeopoldo Luiz dos Santos Neto
Leopoldo Luiz dos Santos Neto
To assess the prevalence of sexual dysfunction in women followed up at the Rheumatology Outpatient Clinic of the Hospital Universitário de Brasília and of the Hospital das Clínicas da Universidade de São Paulo with the following rheumatic diseases: systemic lupus erythematosus; rheumatoid arthritis; systemic sclerosis; antiphospholipid antibody syndrome; and fibromyalgia.

14 March 2019 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
OVon behalf of the Collaborative Group for Studies of Yellow Fever Vaccine
on behalf of the Collaborative Group for Studies of Yellow Fever Vaccine
CFClarissa de Castro Ferreira
Clarissa de Castro Ferreira
ACAna Carolina Campi-Azevedo
Ana Carolina Campi-Azevedo
VPVanessa Peruhype-Magalhāes
Vanessa Peruhype-Magalhāes
JCJordana Grazziela Coelho-Dos-Reis
Jordana Grazziela Coelho-Dos-Reis
LMLicia Maria Henrique Da Mota
Licia Maria Henrique Da Mota
The 17DD-yellow fever (YF) vaccine induces a long-lasting protective immunity, resulting from humoral and cellular immunological memory. The treatment of rheumatoid arthritis (RA) patients with disease-modifying anti-rheumatic drugs (DMARD) may affect pre-existing 17DD-vaccine protective immunity and increase the risk of acquiring YF infection. Our goal was to determine whether DMARD would affect the duration of YF-specific protective immunity in RA patients. A total of 122 RA patients, previously immunized with the 17DD-YF vaccine (1–5, 5–9, and ≥ 10 years) and currently under DMARD therapy, were enrolled in the present investigation. Immunomodulatory therapy encompasses the use of conventional synthetic DMARD alone (csDMARD) or combines with biological DMARD (cs+bDMARD). A total of 226 healthy subjects were recruited as a control group (CONT). Neutralizing antibody responses were measured by a plaque-reduction neutralization test (PRNT), and cellular immunity was evaluated by an in vitro 17DD-YF-specific peripheral blood lymphoproliferative assay. The data demonstrated that csDMARD therapy did not affect the duration of protective immunity induced by the 17DD-YF vaccine compared to that of CONT, as both presented a significant time-dependent decline at 10 years after vaccination. Conversely, cs+bDMARD therapy induced a premature depletion in the main determinants of the vaccine protective response, with diminished PRNT seropositivity levels between 5 and 9 years and impaired effector memory in CD8+ T cells as early as 1–5 years after 17DD-YF vaccination. These findings could support changing the vaccination schedule of this population, with the possibility of a planned booster dose upon the suspension of bDMARD in cases where this is allowed, even before 10 years following 17DD-YF vaccination. The benefit of a planned booster dose should be evaluated in further studies. RBR-946bv5 . Date of registration: March 05, 2018. Retrospectively registered

1 January 2013 in Revista Brasileira de Reumatologia
Verified
Journal Article
Open access
CFClarissa de Castro Ferreira
Clarissa de Castro Ferreira
LMLicia Maria Henrique Da Mota
Licia Maria Henrique Da Mota
AOAna Cristina Vanderley Oliveira
Ana Cristina Vanderley Oliveira
JCJozélio De Carvalho
Jozélio De Carvalho
RLRodrigo Aires Corrêa Lima
Rodrigo Aires Corrêa Lima
LNLeopoldo Luiz dos Santos Neto
Leopoldo Luiz dos Santos Neto